American Journal of Clinical Oncology-Cancer Clinical Trials

The *American Journal of Clinical Oncology-Cancer Clinical Trials* (abbreviated as *Am J Clin Oncol-Canc*; ISSN 0277-3732) serves as a dedicated platform for the dissemination of original research and clinical investigations focused on the diagnosis, management, and treatment of cancer. The journal’s scope encompasses a wide range of topics within clinical oncology, with a particular emphasis on the design, implementation, and results of cancer clinical trials. This includes chemotherapy, radiation therapy, surgical oncology, biologic response modifiers, and emerging targeted therapies, as well as supportive care and quality-of-life assessments. The journal primarily publishes original research articles, clinical trial reports, and comprehensive reviews that synthesize current evidence. It also accommodates case reports, brief communications, and editorials that offer critical perspectives on evolving treatment paradigms. The target audience comprises medical oncologists, radiation oncologists, surgical oncologists, clinical researchers, and healthcare professionals involved in cancer patient care and trial development. Published by Lippincott Williams & Wilkins, the journal offers both subscription-based access and optional open access for individual articles, ensuring flexibility for authors and readers. With an Impact Factor of 1.8000 for 2026 and placement in the fourth quartile (Q4) of the JCR, the journal occupies a niche but supportive role in the oncology literature, particularly for studies that may not meet the threshold of higher-tier journals but retain clinical relevance. Its standing as a Q4 title in the Medicine category indicates that it serves as an accessible outlet for early-stage clinical trial data, regional studies, and practice-oriented research, making it a valuable resource for clinicians seeking pragmatic insights into cancer treatment outcomes.